Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
stocks
5 top US dividend shares from the best managers
These cheap dividend stocks are popular among highly rated concentrated fund managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,191.70 | 13.20 | 0.16% |
| CAC 40 | 8,047.60 | 73.20 | -0.90% |
| DAX 40 | 22,620.95 | 387.99 | -1.69% |
| Dow JONES (US) | 41,911.71 | 890.01 | -2.08% |
| FTSE 100 | 8,600.22 | 79.66 | -0.92% |
| HKSE | 23,783.49 | 447.81 | -1.85% |
| NASDAQ | 17,468.32 | 727.90 | -4.00% |
| Nikkei 225 | 37,028.27 | 141.10 | 0.38% |
| NZX 50 Index | 12,420.18 | 95.79 | -0.77% |
| S&P 500 | 5,614.56 | 155.64 | -2.70% |
| S&P/ASX 200 | 7,962.30 | 14.10 | 0.18% |
| SSE Composite Index | 3,366.16 | 6.38 | -0.19% |